Design Therapeutics (DSGN)
NASDAQ:DSGN
Total Valuation
Design Therapeutics has a market cap or net worth of $639.54M. The enterprise value is $639.98M.
Market Cap$639.54M
Enterprise Value$639.98M
Share Statistics
Design Therapeutics has 61,672,280 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61,672,280
Owned by Insiders17.10%
Owned by Institutions33.58%
Financial Efficiency
Design Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -37.28%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-37.28%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee0.00
Profits Per Employee-1.25M
Employee Count56
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Design Therapeutics is ―. Design Therapeutics’s PEG ratio is -0.20.
PE Ratio―
PS Ratio0.00
PB Ratio2.53
Price to Fair Value2.53
Price to FCF-9.86
Price to Operating Cash Flow-11.22
PEG Ratio-0.20
Income Statement
In the last 12 months, Design Therapeutics had revenue of 0.00 and earned -69.79M in profits. Earnings per share was -1.22.
Revenue0.00
Gross Profit-622.00K
Operating Income-79.47M
Pretax Income-69.79M
Net Income-69.79M
EBITDA-78.84M
Earnings Per Share (EPS)-1.22
Cash Flow
In the last 12 months, operating cash flow was -54.36M and capital expenditures -193.00K, giving a free cash flow of -54.55M billion.
Operating Cash Flow-54.36M
Free Cash Flow-54.55M
Free Cash Flow per Share-0.88
Dividends & Yields
Design Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change188.06%
50-Day Moving Average10.27
200-Day Moving Average7.37
Relative Strength Index (RSI)50.35
Average Volume (3m)213.56K
Important Dates
Design Therapeutics upcoming earnings date is May 11, 2026, After Close (Confirmed).
Last Earnings DateMar 9, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
Design Therapeutics as a current ratio of 17.14, with Debt / Equity ratio of 0.30%
Current Ratio17.14
Quick Ratio17.14
Debt to Market Cap<0.01
Net Debt to EBITDA0.21
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Design Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Design Therapeutics EV to EBITDA ratio is -6.61, with an EV/FCF ratio of -9.56.
EV to Sales0.00
EV to EBITDA-6.61
EV to Free Cash Flow-9.56
EV to Operating Cash Flow-9.59
Balance Sheet
Design Therapeutics has $219.84M in cash and marketable securities with $645.00K in debt, giving a net cash position of $219.20M billion.
Cash & Marketable Securities$219.84M
Total Debt$645.00K
Net Cash$219.20M
Net Cash Per Share$3.55
Tangible Book Value Per Share$3.71
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Design Therapeutics is $15.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$15.50
Price Target Upside73.38% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-40.26%